Package delivery

Courtesy of John Heiss

Your body is teeming with mysterious particles called vaults. With an average of 10,000 to 100,000 of them in every human cell, they’re thought to be one of the most abundant particles in the body. But no one knows their function.

This mystery doesn’t phase the discoverer of vaults, University of California, Los Angeles cell biologist Leonard Rome. To him, what matters about vaults is not what they do naturally in the body, but what they can do. Vaults’ structure, he says—three proteins and a small RNA molecule assembled in a hollow, barrel-like shape—makes them the perfect nanoscale delivery vehicle to encapsulate and carry therapeutic drugs or genes.

Rome’s lab first encountered vaults almost 25 years ago while studying lysosomal enzymes. In electron microscopy scans of coated vesicles, which shuttle the enzymes through the cytoplasm, postdoc Nancy Kedersha observed what seemed to be a contaminant: smaller particles with an unusual shape. “Our curiosity got the best of us,” Rome recalls, “and by the time we figured out they were not related to coated vesicles, we got hooked on what they were.”

The lab spent 15 years trying to pin down vaults’ function, to no avail. (The team speculates that the particle may take part in detoxifying cells, or ferrying proteins to the nucleus.) Then, in 2001, they made a discovery that transformed their efforts from disheartening to promising. Although vaults are made up of three proteins and an RNA molecule, their most abundant component is major vault protein (MVP). The researchers found that simply expressing MVP in cells caused them to form vault-like structures (J Biol Chem 276:23217–20, 2001). This finding got Rome thinking: It could be relatively easy to make delivery vehicles—just get cells to express MVP. Since vaults are endogenous molecules, they likely wouldn’t be immunogenic—a problem that has dogged drug delivery efforts to date.

They soon identified a domain in a second vault protein that acts a vault “zip code,” says Rome; when attached to other molecules, it can pull essentially any compound into the vault particles. And by adding antibodies or other targeting moieties to the c-terminal end of the MVP protein, the researchers could direct a loaded vault to a specific cell type (ACS Nano 3: 27036, 2009). They also figured out how to protect the cargo. Vaults—like other types of particles—enter cells through endosomes, but proteins brought in by endosome are often digested. Rome and Glen Nemerow, a viral immunologist at the Scripps Research Institute in California, got around that problem with the help of pVI, an adenovirus protein that springs the virus particles free from endosomes and into the cytoplasm. By attaching pVI onto vaults, they could boost how much vault cargo—here, a GFP-encoded plasmid—made it into the cytoplasm (ASC Nano, 3:691–99, 2009).

Putting a mysterious particle to work

Over the years, Rome’s lab has had many collaborators. Kathleen Kelly, a pathologist at UCLA and a coauthor on the targeting paper, learned about vaults in a UCLA seminar Rome gave; now the duo are using vaults to deliver a chlamydia vaccine, which recently showed promising results in mice (PLoS ONE 4(4):e5409, 2009). Rome’s lab, though, is probably the only one in the world studying vaults full time, he says; without a known function, they’re “not really a textbook particle.” Other researchers often ask him, “How come I don’t know about this?”

Francis Szoka, a drug delivery scientist at the University of California, San Francisco, for one, had never heard of vaults. “I really think the structural biology and biochemistry is magnificent,” he says after a look at the Rome lab’s Web site and the abstracts of a couple recent studies. But he isn’t convinced of vaults’ drug delivery potential. Modifying an already complex molecule might make vaults more immunogenic than they currently seem. “Even human proteins can elicit an immunogenic response to human antibody,” he cautions. Plus, the literature is filled with delivery systems that seemed promising but proved problematic in vivo. “You’re asking me, is their baby beautiful,” he says. “Yes, it’s a beautiful baby. But we don’t know how it’s going to grow up.”



Advertisement


 

Rate this article

Rating: 3.94/5 (48 votes )





Intracellular Barrels
by anonymous poster

[Comment posted 2010-03-20 09:16:08]
They look like little hand grenades - could these be the apoptosis particle we've all been searching for? (Sarcasm alert).



Size Does Matter
by Keith Loritz

[Comment posted 2010-03-19 19:09:42]
With 10,000 to 100,000 per cell, they must be very, very small. Just how much volume do these vaults hold?



Vaults
by Robert Birdwell

[Comment posted 2010-03-19 16:40:06]
let's see here, a lab has been studying "Vaults" for years; know very little or nothing about them, and have already concluded they can use them to deliver drugs to human cells.

Me thinks they have the cart before the horse.

I read this article as a conclusion in search of a premis to deliver fame and fortune to the vault wizards and much pain, misery, and a really big oops, when their victims begin dropping like flies in a DDT factory.

Oh, but wait! These people work for prestigious universities and are certified EXPERTS! This is science and nothing can possibly go wrong!!!!






Front Cover

Register for FREE Online Access

  • »Current issue
  • »Best Places to Work and Salary surveys
  • »Daily news and monthly contents emails

Register »

Subscribe to the Magazine

  • »Monthly print issues
  • »Unlimited online access
  • »Special offers on books, apparel, and more

Subscribe »

Library Subscriptions
Recommend to a Librarian

Masthead | Contact | Advertise | Privacy Policy
© 1986-2012 The Scientist